TO THE EDITOR-We read with interest the article by Vydra and colleagues about enterococcal bloodstream infections (EBSIs) in hematopoietic stem cell transplant (HSCT) recipients [1] . In their experience, the incidence of EBSI was 12%, and in 61 adult patients 66% of enterococci were resistant to vancomycin (VRE) [1] . The mortality 30 days after EBSI was 38% for both VRE and vancomycin-susceptible enterococci (VSE), and EBSI, particularly due to VRE, was associated with lower 1-year survival [1] . Using the same statistical approach, we reviewed our experience, based on new data and a reanalysis of a previous study [2] .
VRE, and 65% (95% CI, 61%-69%) for patients without EBSI, compared with 48% for VSE, 23% for VRE, and 63% for no EBSI reported by Vydra and colleagues. The 1-year nonrelapse mortality was 63% (95% CI, 47%-80%) for all EBSIs, 64% (95% CI, 47%-81%) for VSE, 44% (95% CI, 13%-90%) for VRE, and 23% (95% CI, 19%-27%) for patients without EBSI, compared with 33% for VSE, 53% for VRE, and 22% for no EBSI reported by Vydra and colleagues. However, when evaluating the hazard ratio for all-cause mortality in patients with EBSI, we found that the impact of EBSI was most prominent during the first 3 months after HSCT, although it persisted at 12 months as well (Table 1) .
In summary, 2 main differences emerged between the 2 studies. First, the overall mortality associated with EBSIs, irrespective of vancomycin susceptibility, was as high as the one reported for VRE by Vydra and colleagues, even though most of the infections were due to VSE and vancomycin was included in initial empirical therapy. Thus, in our experience, and contrary to what has been reported by others [2, 3] , we did not find any difference in mortality depending on vancomycin susceptibility. Second, EBSI, due to both VSE and VRE, had a significant impact not only on the longterm but especially on the short-term risk of all-cause mortality as compared to patients without EBSI, data that were not shown by Vydra and colleagues.
We confirm that EBSI is a marker of poor short-and long-term outcome. More clinical and microbiological data are necessary to explain why in our center VSE were associated with lower survival compared to Vydra and colleagues, despite no difference between the 2 studies in overall survival and nonrelapse mortality among patients without EBSI and lower mortality 30 days after EBSI.
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